Search

Your search keyword '"Wedel, Hans"' showing total 899 results
Start Over Author "Wedel, Hans"
899 results on '"Wedel, Hans"'

51. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

Author

Dahlof, Bjorn, Sever, Peter S., Poulter, Neil R., Wedel, Hans, Beevers, D. Gareth, Caulfield, Mark, Collins, Rory, Kjeldsen, Sverre E., Kristinsson Ami McInnes, Gordon T., Mehlsen, Jesper, Nieminen, Markku, O'Brien, Eoin, and Ostergen, Jan

Subjects
Hypertension -- Drug therapy, Antihypertensive drugs -- Evaluation, Antihypertensive drugs -- Dosage and administration
Published
2005

53. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery

Author

Sjostrom, Lars, Lindroos, Anna-Karin, Peltonen, Markku, Torgerson, Jarl, Bouchrad, Cluade, Carlsson, Bjorn, Larsson, Bo, Dahlgren, Sven, Narbro, Kristina, Sjostrom, Carl David, Sullivan, Marianne, and Wedel, Hans

Subjects
Obesity -- Risk factors, Obesity -- Care and treatment, Cardiovascular system -- Surgery, Cardiovascular system -- Methods
Abstract

Swedish Obese subjects (SOS) study is conducted to examine changes in cardiovascular risk factors over follow-up periods of 2 and 10 years in surgically treated subjects and contemporaneously matched, conventionally treated control subjects. The findings indicate that bariatric surgery is a viable option for the treatment of severe obesity, resulting in long-term weights loss and improved lifestyle.

Published
2004

56. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For Endpoint Reduction (LIFE) substudy

Author

Kjeldsen, Sverre E., Dahlof, Bjorn, Devereux, Richard B., Julius, Stevo, Aurup, Peter, Edelman, Jonathan, Beevers, Gareth, Faire, Ulf de, Fyhrquist, Frej, Ibsen, Hans, Kristianson, Krister, Lederballe-Pedersen, Ole, Lindholm, Lars H., Nieminen, Markku S., Omvik, Per, Oparil, Suzanne, Snapinn, Steven, and Wedel, Hans

Subjects
Losartan -- Evaluation, Hypertension -- Drug therapy
Abstract

The drug losartan is more effective than atenolol in lowering blood pressure in patients with systolic high blood pressure, according to a study of 1,326 patients. Losartan belongs to a group of drugs called angiotensin II receptor blockers. Although both drugs lowered blood pressure, patients who took losartan were less likely to have a stroke, develop diabetes, or die from cardiovascular disease.

Published
2002

59. Bariatric Surgery and Long-term Cardiovascular Events

Author

Sjöström, Lars, Peltonen, Markku, Jacobson, Peter, Sjöström, C. David, Karason, Kristjan, Wedel, Hans, Ahlin, Sofie, Anveden, Åsa, Bengtsson, Calle, Bergmark, Gerd, Bouchard, Claude, Carlsson, Björn, Dahlgren, Sven, Karlsson, Jan, Lindroos, Anna-Karin, Lönroth, Hans, Narbro, Kristina, Näslund, Ingmar, Olbers, Torsten, Svensson, Per-Arne, and Carlsson, Lena M.

Published
2012
Full Text
View/download PDF

66. Contributors

Author

Asmar, Roland, primary, Basile, Jan N., additional, Beevers, D.G., additional, Beilin, Lawrence J., additional, Bilo, Grzegorz, additional, Black, Henry R., additional, Boerrigter, Guido, additional, Bone, Lee R., additional, Brunner, Hans, additional, Burnett, John C., additional, Calhoun, David A., additional, Campese, Vito M., additional, Carey, Robert M., additional, Caro, J. Jaime, additional, Carretero, Oscar A., additional, Chappell, Mark C., additional, Chrysant, George S., additional, Cutler, Jeffrey A., additional, Dahlöf, Björn, additional, da Silva, Alexandre A., additional, de Faire, Ulf, additional, Delgado, Maria Carolina, additional, Devereux, Richard B., additional, Diamond, Joseph A., additional, DiPette, Donald J., additional, Diz, Debra I., additional, Edelman, Jonathan M., additional, Elliott, William J., additional, Ekman, Steffan, additional, Falkner, Bonita, additional, Fan, William L., additional, Fenichel, Robert R., additional, Ferrario, Carlos M., additional, Franklin, Stanley S., additional, Freis, Edward D., additional, Frishman, William H., additional, Frohlich, Edward D., additional, Funder, John W., additional, Fyhrquist, Frej, additional, Gamba, Gerardo, additional, Gami, Apoor S., additional, Gavras, Haralambos, additional, Gavras, Irene, additional, Gehr, Todd W.B., additional, Gleim, Gilbert W., additional, Hall, John E., additional, Hanes, Donna S., additional, Harrap, tephen B., additional, Harris, Katherine E., additional, Haus, Erhard, additional, Hermida, Ramon C., additional, Hill, Martha N., additional, Ibsen, Hans, additional, Intengan, Hope, additional, Izzo, Joseph L., additional, Jennings, Garry L.R., additional, Johnson, Ernest F., additional, Johnston, Colin I., additional, Jones, Daniel W., additional, Julius, Stevo, additional, Kannel, William B., additional, Katki, Khurshed A., additional, Kjeldsen, Sverre E., additional, Kleyman, Thomas R., additional, Knepper, Mark A., additional, Kokkoris, Panagiotis, additional, Kostis, John B., additional, Krakoff, Lawrence R., additional, Kristianson, Krister J., additional, Kuo, Jay J., additional, Lakkis, Jay, additional, Laragh, John H., additional, Levine, David M., additional, Light, Kathleen C., additional, Lindholm, Lars H., additional, Liu, Jiankang, additional, Lüscher, Thomas F., additional, Mancia, Giuseppe, additional, Mansoor, George A., additional, McCarron, David A., additional, McGuire, Heather L., additional, McInnes, Gordon T., additional, McMahon, Ellen G., additional, Meyer, Renee P., additional, Miller, Nancy Houston, additional, Nadim, Mitra K., additional, Nesbitt, Shawna D., additional, Neutel, Joel M., additional, Nieminen, Markku S., additional, Nussberger, Jürg, additional, Omvik, Per, additional, Oparil, Suzanne, additional, Opie, Lionel H., additional, Osterberg, Lars, additional, Parati, Gianfranco, additional, Payne, Krista A., additional, Pedersen, Ole Lederballe, additional, Phillips, Robert A., additional, Pi-Sunyer, Xavier, additional, Plat, Francis, additional, Pool, James L., additional, Portaluppi, Francesco, additional, Prisant, L. Michael, additional, Puddey, Ian B., additional, Raj, Satish R., additional, Reaven, Gerald M., additional, Reeves, Scott T., additional, Reinberg, Alain, additional, Reiser, Ira W., additional, Reudelhuber, Timothy L., additional, Reusser, Molly E., additional, Reves, J.G., additional, Rhaleb, Nour-Eddine, additional, Robertson, David, additional, Roccella, Edward J., additional, Rudd, Peter, additional, Ruddy, Michael C., additional, Ruilope, Luis Miguel, additional, Schiffrin, Ernesto L., additional, Schirger, John A., additional, Schork, M. Anthony, additional, Shepherd, Alexander M.M., additional, Sica, Domenic A., additional, Siragy, Helmy M., additional, Smith, Beverly A., additional, Smolensky, Michael H., additional, Snapinn, Steven, additional, Somers, Virend K., additional, Spieker, Lukas E., additional, Spitalewitz, Samuel, additional, Stolt, Pelle, additional, Supowit, Scott C., additional, Svetkey, Laura P., additional, Taler, Sandra J., additional, Tallam, Lakshmi S., additional, Tallant, E. Ann, additional, Tikellis, Chris, additional, Turnbull, Fiona, additional, Vidt, Donald G., additional, Watson, Ralph E., additional, Weber, Michael A., additional, Wedel, Hans, additional, Weder, Alan B., additional, Weinberger, Myron H., additional, Weir, Matthew R., additional, White, William B., additional, Wofford, Marion R., additional, Wong, Nathan D., additional, Wright, Jackson T., additional, Yang, Xiao-Ping, additional, Young, William F., additional, Zanchetti, Alberto, additional, and Zhao, Huawei, additional

Published
2005
Full Text
View/download PDF

67. The LIFE Study

Author

Dahlöf, Björn, primary, Devereux, Richard B., additional, Kjeldsen, Sverre E., additional, Julius, Stevo, additional, Beevers, D.G., additional, de Faire, Ulf, additional, Fyhrquist, Frej, additional, Ibsen, Hans, additional, Kristianson, Krister, additional, Pedersen, Ole Lederballe, additional, Lindholm, Lars H., additional, Nieminen, Markku S., additional, Omvik, Per, additional, Oparil, Suzanne, additional, Wedel, Hans, additional, Edelman, Jonathan M., additional, Snapinn, Steve, additional, Harris, Katherine E., additional, and Gleim, Gilbert W., additional

Published
2005
Full Text
View/download PDF

68. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide

Author

Wedel, Hans, McMurray, John J.V., Lindberg, Magnus, Wikstrand, John, Cleland, John G.F., Cornel, Jan H., Dunselman, Peter, Hjalmarson, Åke, Kjekshus, John, Komajda, Michel, Kuusi, Timo, Vanhaecke, Johan, and Waagstein, Finn

Published
2009
Full Text
View/download PDF

77. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease

Author

Johannesson, Magnus, Jonsson, Bengt, Kjekshus, John, Olsson, Anders G., Pedersen, Terje R., and Wedel, Hans

Subjects
Simvastatin -- Health aspects, Hypercholesterolemia -- Drug therapy, Coronary heart disease -- Economic aspects
Abstract

Simvastatin appears to be cost-effective treatment for patients with heart disease. Simvastatin lowers cholesterol levels. Researchers used data from a Scandinavian study to estimate the cost effectiveness of simvastatin treatment according to age, sex, and cholesterol value prior to treatment. Direct cost savings from the reduction in costs associated with heart attacks ranged from $3,800 per year of life to $27,400, although savings disappeared among the elderly when the indirect costs of lost productivity were factored in. Results do not apply to prevention of heart disease.

Published
1997

81. Evaluation of the dual peroxisome proliferator–activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial

Author

Lincoff, Michael A., Tardif, Jean-Claude, Neal, Bruce, Nicholls, Stephen J., Rydén, Lars, Schwartz, Gregory G., Malmberg, Klas, Buse, John B., Henry, Robert R., Wedel, Hans, Weichert, Arlette, Cannata, Ruth, and Grobbee, Diederick E.

Published
2013
Full Text
View/download PDF

82. The impact of serum uric acid on cardiovascular outcomes in the LIFE study

Author

Høieggen, Aud, Alderman, Michael H., Kjeldsen, Sverre E., Julius, Stevo, Devereux, Richard B., de Faire, Ulf, Fyhrquist, Frej, Ibsen, Hans, Kristianson, Krister, Lederballe-Pedersen, Ole, Lindholm, Lars H., Nieminen, Markku S., Omvik, Per, Oparil, Suzanne, Wedel, Hans, Chen, Cong, Dahlöf, Björn, and for the LIFE Study Group

Published
2004
Full Text
View/download PDF

86. HbA(1c) level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study

Author

Lind, Marcus, Pivodic, Aldina, Svensson, Ann-Marie, Olafsdottir, Arndis F., Wedel, Hans, Ludvigsson, Johnny, Lind, Marcus, Pivodic, Aldina, Svensson, Ann-Marie, Olafsdottir, Arndis F., Wedel, Hans, and Ludvigsson, Johnny

Abstract

OBJECTIVE To evaluate if the lowest target level for glycated haemoglobin (HbA(1c)) of amp;lt; 6.5% is associated with lower risk for retinopathy and nephropathy than less tight control in children and adults with type 1 diabetes. DESIGN Population based cohort study. SETTING Swedish National Diabetes Registry, 1 January 1998 to 31 December 2017. PARTICIPANTS 10 398 children and adults with type 1 diabetes followed from diagnosis, or close thereafter, until end of 2017. MAIN OUTCOME MEASURES Relative risk (odds ratios) for retinopathy and nephropathy for different mean levels of HbA(1c). RESULTS Mean age of participants was 14.7 years (43.4% female), mean duration of diabetes was 1.3 years, and mean HbA(1c) level was 8.0% (63.4 mmol/mol). After adjustment for age, sex, duration of diabetes, blood pressure, blood lipid levels, body mass index, and smoking, the odds ratio for mean HbA(1c) amp;lt; 6.5% (amp;lt; 48 mmol/mol) compared with 6.5-6.9% (48-52 mmol/mol) for any retinopathy (simplex or worse) was 0.77 (95% confidence interval 0.56 to 1.05, P=0.10), for preproliferative diabetic retinopathy or worse was 3.29 (0.99 to 10.96, P=0.05), for proliferative diabetic retinopathy was 2.48 (0.71 to 8.62, P=0.15), for microalbuminuria or worse was 0.98 (0.60 to 1.61, P=0.95), and for macroalbuminuria was 2.47 (0.69 to 8.87, P=0.17). Compared with HbA(1c) levels 6.56.9%, HbA(1c) levels 7.0-7.4% (53-57 mmol/mol) were associated with an increased risk of any retinopathy (1.31, 1.05 to 1.64, P=0.02) and microalbuminuria (1.55, 1.03 to 2.32, P=0.03). The risk for proliferative retinopathy (5.98, 2.10 to 17.06, Pamp;lt;0.001) and macroalbuminuria (3.43, 1.14 to 10.26, P=0.03) increased at HbA(1c) levels amp;gt; 8.6% (amp;gt; 70 mmol/mol). The risk for severe hypoglycaemia was increased at mean HbA(1c) amp;lt; 6.5% compared with 6.5-6.9% (relative risk 1.34, 95% confidence interval 1.09 to 1.64, P=0.005). CONCLUSIONS Risk of retinopathy and nephropathy did not differ at HbA(1c), Funding Agencies|Swedish government; Novonordisk Foundation

Published
2019
Full Text
View/download PDF

87. Resolute zotarolimus‐eluting stent in ST‐elevation myocardial infarction (resolute‐STEMI): A prespecified prospective register from the DAPT‐STEMI trial

Author

Postma, Warner, Fabris, Enrico, Ent, Martin Van der, Hermanides, Rik, Buszman, Pawel, Birgelen, Clemens Von, Cook, Stéphane, Wedel, Hans, Luca, Giuseppe De, Delewi, Ronak, Zijlstra, Felix, Kedhi, Elvin, Postma, Warner, Fabris, Enrico, Ent, Martin Van der, Hermanides, Rik, Buszman, Pawel, Birgelen, Clemens Von, Cook, Stéphane, Wedel, Hans, Luca, Giuseppe De, Delewi, Ronak, Zijlstra, Felix, and Kedhi, Elvin

Abstract

To evaluate the safety and efficacy outcomes after primary percutaneous coronary intervention (pPCI) with second‐generation Resolute™ zotarolimus‐eluting stent (R‐ ZES) in patients enrolled in the DAPT‐STEMI Trial (NCT01459627).Background: R‐ ZES is one of the most used drug eluting stents worldwide. To date, the safety and efficacy data of this stent in setting of STEMI is limited.Methods: The Resolute‐STEMI is a prespecified prospective register that reports the safety and efficacy of R‐ZES in setting of ST‐Elevation Myocardial Infarction (STEMI) at 6 months for the following endpoints: a composite endpoint of all‐cause mortality, any myocardial infarction (MI), any (unscheduled) revascularization, stroke and TIMI major bleeding, as well as target lesion failure and stent thrombosis (ST).Results: From a total of 1,100 STEMI patients enrolled in the trial, 998 received a R‐ZES. At 6 months the PE occurred in 42 (4.2%) patients. All‐cause death, MI, revascularization, stroke and TIMI major bleeding was respectively 8 (0.8%), 9 (0.8%), 34 (3.4%), 2 (0.2%), and 4 (0.4%). The rate of target lesion revascularizations involving the culprit lesion was 1.1%. Target lesion failure was 1.5%. The rate of definite ST was 0.5%. The rate of both definite or probable ST was 0.7%.Conclusions: The present analysis is the largest to date reporting short‐ term and mid‐term clinical outcomes with the R‐ZES stent in setting of STEMI. At 30 days and 6‐months R‐ZES has an outstanding safety and efficacy even in this high‐ risk category of patients.

Published
2019

92. Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study

Author

Wachtell, Kristian, Ibsen, Hans, Olsen, Michael H., Borch-Johnsen, Knut, Lindholm, Lars H., Mogensen, Carl Erik, Dahlöf, Björn, Devereux, Richard B., Beevers, Gareth, de Faire, Ulf, Fyhrquist, Frej, Julius, Stevo, Kjeldsen, Sverre E., Kristianson, Krister, Lederballe-Pedersen, Ole, Nieminen, Markku S., Okin, Peter M., Omvik, Per, Oparil, Suzanne, Wedel, Hans, Snapinn, Steven M., and Aurup, Peter

Published
2003

93. Effects of Losartan or Atenolol in Hypertensive Patients without Clinically Evident Vascular Disease: A Substudy of the LIFE Randomized Trial

Author

Devereux, Richard B., Dahlöf, Björn, Kjeldsen, Sverre E., Julius, Stevo, Aurup, Peter, Beevers, Gareth, Edelman, Jonathan M., de Faire, Ulf, Fyhrquist, Frej, Sigrid Helle Berg, Ibsen, Hans, Kristianson, Krister, Lederballe-Pedersen, Ole, Lindholm, Lars H., Nieminen, Markku S., Omvik, Per, Oparil, Suzanne, Snapinn, Steven, and Wedel, Hans

Published
2003

96. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

Author

Wedel, Hans

Subjects
Heart attack -- Drug therapy, Enalapril -- Health aspects
Abstract

Treatment with enalapril may prevent hospitalization for heart failure and increase survival of patients with asymptomatic left ventricular dysfunction. In patients with left ventricular dysfunction, the heart is unable to pump enough blood to the body. Of 4,228 patients with asymptomatic left ventricular dysfunction, 2,111 were treated with enalapril, and 2,117 received a placebo, an inactive substance. Treatment with enalapril decreased the risk of death by eight percent, and the risk of death from cardiovascular causes by 12%. Thirty percent of the patients in the the enalapril group developed heart failure or died, compared to 39% of those in the placebo group. Of all patients who developed heart failure, patients treated with enalapril developed heart failure after an average of 22 months, compared to an average of eight months for those who received a placebo. Twenty-one percent of the patients treated with enalapril died or were hospitalized for heart failure, compared with 25% of those who received a placebo.

Published
1992

98. Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)

Author

Hjalmarson, Åke, Goldstein, Sidney, Fagerberg, Björn, Wedel, Hans, Waagstein, Finn, Kjekshus, John, Wikstrand, John, El Allaf, Dia, Vítovec, Jirí, Aldershvile, Jan, Halinen, Matti, Dietz, Rainer, Neuhaus, Karl-Ludwig, Jánosi, András, Thorgeirsson, Gudmundur, Dunselman, Peter H. J. M., Gullestad, Lars, Kuch, Jerzy, Herlitz, Johan, Rickenbacher, Peter, Ball, Stephen, Gottlieb, Stephen, and Deedwania, Prakash

Published
2000

99. Impact of Thrombus Aspiration on Mortality, Stent Thrombosis, and Stroke in Patients With ST-Segment-Elevation Myocardial Infarction : A Report From the Swedish Coronary Angiography and Angioplasty Registry

Author

Angeras, Oskar, Haraldsson, Inger, Redfors, Bjorn, Frobert, Ole, Petursson, Petur, Albertsson, Per, Ioanes, Dan, Odenstedt, Jacob, Olsson, Hans, Witt, Nils, Ruck, Andreas, Millgard, Jonas, Nilsson, Johan, Persson, Jonas, Soderbom, Mans, Wedel, Hans, Erlinge, David, James, Stefan, Ramunddal, Truls, and Omerovic, Elmir

Subjects
myocardial infarction, Kardiologi, thrombectomy, Cardiac and Cardiovascular Systems, cardiovascular diseases, primary percutaneous coronary intervention
Abstract

Background-Thrombus aspiration is still being used in a substantial number of patients despite 2 large randomized clinical trials showing no favorable effect of routine thrombus aspiration during primary percutaneous coronary intervention in patients with STsegment- elevation myocardial infarction. The aim of this observational study was to evaluate the impact of thrombus aspiration on mortality, stent thrombosis, and stroke using all available data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Methods and Results-We identified 42 829 consecutive patients registered in SCAAR between January 2005 and September 2014 who underwent percutaneous coronary intervention for ST-segment-elevation myocardial infarction. Thrombus aspiration was used in 25% of the procedures. We used instrumental variable analysis with administrative healthcare region as the treatmentpreference instrumental variable to evaluate the effect of thrombus aspiration on mortality, stent thrombosis, and stroke. Thrombus aspiration was not associated with mortality at 30 days (risk reduction: -1.2; 95% confidence interval [CI], -5.4 to 3.0; P=0.57) and 1 year (risk reduction: -2.4; 95% CI, -7.6 to 3.0; P=0.37). Thrombus aspiration was associated with a lower risk of stent thrombosis both at 30 days (risk reduction: -2.7; 95% CI, -4.1 to -1.4; P

Published
2018

100. Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial

Author

Koomen, Jeroen V., primary, Heerspink, Hiddo J. L., additional, Schrieks, Ilse C., additional, Schwartz, Gregory G., additional, Lincoff, A. Michael, additional, Nicholls, Stephen J., additional, Svensson, Anders, additional, Wedel, Hans, additional, Weichert, Arlette, additional, Grobbee, Diederick E., additional, and Stevens, Jasper, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results